MFG
LEXX icon

Merit Financial Group’s Lexaria Bioscience LEXX Stock Holding History

Merit Financial Group’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-21,267
Closed -$63K – 613
2022
Q2 		$63K Buy
+21,267
New +$57K ﹤0.01% 549

Other funds holding LEXX

ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
CC
Centiva Capital New York $13.6B AUM 20% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Merit Financial Group's LEXX Position: Q3 2022 in Review

Merit Financial Group sold out of Lexaria Bioscience (LEXX) in Q3 2022, closing a stake of 21,267 shares — an estimated $63K sold.

Merit Financial Group first reported a position in LEXX in Q2 2022 and held it in 1 quarter. The position peaked at $63K in Q2 2022. 16 funds tracked by Wall St. Rank hold LEXX as of Q3 2022.

  • Merit Financial Group reported no remaining Lexaria Bioscience position as of Q3 2022 after selling out during the quarter.
  • Merit Financial Group sold 21,267 Lexaria Bioscience shares in Q3 2022, an estimated $63K.
  • Merit Financial Group first reported a position in Lexaria Bioscience in Q2 2022 and held it in 1 quarter.
  • Merit Financial Group's Lexaria Bioscience position peaked at $63K in Q2 2022.
  • 16 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q3 2022.

Based on Merit Financial Group's 13F filing for Q3 2022, filed 31 Oct 2022.